Business Context and Reporting Period
Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed Form 6-K for the month of November 2025. The filing reports on a specific corporate announcement made to the Australian Securities Exchange on November 18, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The material change reported is the receipt of approval from the Therapeutic Goods Administration (TGA) for a Phase 1 therapeutic trial of the company's candidate drug, RAD 402.
Guidance, Outlook, and Risks
Management commentary is limited to the notification of the regulatory approval for the RAD 402 trial. The filing does not contain specific financial guidance, updated outlooks, or detailed risk factors beyond the standard legal disclaimers regarding the non-filing status of the report under the Exchange Act.
Investor Verification Checklist
- Verify the full text of the attached Public Notice (Exhibit 99.1) regarding the RAD 402 Phase 1 trial approval.
- Confirm the specific scope and timeline of the approved therapeutic trial.
- Review subsequent filings for any financial impact or capital requirements associated with initiating the trial.